** Shares of drug developer Cassava Sciences SAVA.O rise 2.82% to $2.19 premarket
** Co says the U.S. Department of Justice has ended its probe into the company regarding allegations of research misconduct for its experimental Alzheimer's drug simufilam
** Co says probe ended four months after the Justice Department dismissed a criminal indictment accusing former adviser Hoau-Yan Wang, who allegedly submitted false data regarding the drug
** SAVA shares fell 16.1% in 2025
(Reporting by Gnaneshwar Rajan in Bengaluru)
((Gnaneshwar.Rajan@thomsonreuters.com;))